FDA Accepts Supplement Application for Celecoxib by Alembic
The FDA has accepted a supplemental application for Celecoxib (ANDA204519) submitted by Alembic.
Asset / Drug
Drug and asset intelligence for Celecoxib with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
COX-2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.